This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Corneal Versus Conjunctival Delivery Using a Delivery Device

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00143429
First received: September 1, 2005
Last updated: March 4, 2015
Last verified: March 2015
September 1, 2005
March 4, 2015
Not Provided
Not Provided
IOP level in the study eye
Same as current
Complete list of historical versions of study NCT00143429 on ClinicalTrials.gov Archive Site
Change in ocular safety assessments. Ocular and systemic adverse events throughout the study period
  • Change in ocular safety assessments.
  • Ocular and systemic adverse events throughout the study period
Not Provided
Not Provided
 
Corneal Versus Conjunctival Delivery Using a Delivery Device
Effect Of Corneal Versus Conjunctival Delivery On The Corneal Safety, Tolerability, and Antihypertensive Efficacy Of The Xalatan Ophthalmic Delivery Device
Compare the antihypertensive efficacy of three methods for installing Xalatan
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single
Primary Purpose: Treatment
  • Glaucoma, Open-Angle
  • Ocular Hypertension
Drug: Xalatan
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
Not Provided
Not Provided

Inclusion Criteria:

  • Diagnosis of primary open angle glaucoma or ocular hypertension in 1 or both eyes

Exclusion Criteria:

  • History of closed/barely open anterior chamber angle or a history of angle closure
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT00143429
A6111127
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP